Prothya Biosolutions

Focus: Prothya Biosolutions is a Belgium-based biotech company specializing in plasma-derived medicinal products and related services across infectious diseases, immunology, and rare diseases. Founded in 2021, the company operates a diverse clinical pipeline spanning multiple therapeutic areas.

Infectious Diseases Immunology Rare Diseases Dermatology

Profile data last refreshed 4d ago · AI intelligence enriched 2w ago

Open Jobs

About Prothya Biosolutions

AI assessmentNot Hiring

No open roles listed right now. Follow Prothya Biosolutions to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Data Registry of Auto Immune Hemolytic Anemia

Autoimmune Hemolytic Anemia

N/A

Clinical Trials (1)

NCT04024202Data Registry of Auto Immune Hemolytic Anemia

N/A

Help build intelligence for Prothya Biosolutions

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Broad pipeline with 26 active trials across Phase 1-4, including advanced programs in hemophilia, immunodeficiency, and angioedema with near-term commercial potential.
Diversified therapeutic focus across infectious diseases, immunology, rare diseases, dermatology, and hematology reduces single-asset risk and enables cross-functional learning.
Plasma-derived product expertise in a category with sustained clinical demand and regulatory predictability, particularly for immunoglobulin and coagulation factor programs.

Watch Out For

No active job openings at time of data collection and missing employee count data suggest early-stage scaling or potential hiring freeze.
Founded in 2021 with no disclosed funding, revenue, or financial metrics raises questions about sustainability, cash runway, and long-term stability.

Generated by Claude from Prothya Biosolutions's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

a human hepatitis B immunoglobulin solution for injection for intramuscular administration

Healthy

Phase 1

Clinical Trials (1)

NCT03899142Pharmacokinetics of New HepBQuin

Phase 1

succinylated human serum albumin

HIV Infections

Phase 1/2

Clinical Trials (1)

NCT00128063Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection

Phase 1/2